Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ARDS) and infant respiratory distress syndrome (IRDS)
View Patent ↗A composition comprising a combination of a compound of formula I in which R1 is hydrogen or 2-(2-hydroxyethoxy)ethyl and/or a pharmacologically tolerable salt thereof, and lung surfactant is useful for treating patients afflicted with IRDS or ARDS.
1. A composition for the treatment of IRDS and ARDS comprising
a) a compound of formula I
in which R1 is hydrogen or 2-(2-hydroxyethoxy)ethyl and/or a pharmacologically tolerable salt of this compound and b) a phospholipid comprising lung surfactant.
2. A composition for the treatment of IRDS and ARDS comprising 4-(2,6-dichloroanilino)-3-thio-phene-acetic acid and/or one of its pharmacologically tolerable salts and a phospholipid comprising lung surfactant.
3. A composition as claimed in claim 1 , wherein the lung surfactant comprises a mixture of phospholipids.
4. A composition as claimed in claim 3 , wherein the phospholipids are those which occur in natural lung surfactant.
5. A composition as claimed in claim 3 , which further comprises lung surfactant protein.
6. A composition as claimed in claim 5 , wherein the lung surfactant protein is a member selected from the group consisting of SP-B, SP-C and a modified derivative of either.
7. A composition as claimed in claim 1 , wherein the lung surfactant is that obtained by pulmonary lavage.
8. A composition as claimed in claim 2 , wherein the lung surfactant comprises a mixture of phospholipids.
9. A composition as claimed in claim 8 , wherein the phospholipids are those which occur in natural lung surfactant.
10. A composition as claimed in claim 4 , which further comprises lung surfactant protein.
11. A composition as claimed in claim 10 , wherein the lung surfactant protein is a member selected from the group consisting of SP-B, SP-C and a modified derivative of either.
12. A method of compounding a pharmaceutical composition for controlling IRDS and ARDS which comprises combining a phospholipid comprising lung surfactant with a compound of formula I,
in which R1 is hydrogen or 2-(2-hydroxyethoxy)ethyl, or a pharmacologically tolerable salt thereof.
13. A method of treating a patient afflicted with IRDS or ARDS, which comprises administering to the patient an effective amount of a composition as claimed in claim 1 .
14. A method of treating a patient afflicted with IRDS or ARDS, which comprises administering to the patient an effective amount of a composition as claimed in claim 2 .
15. A method of claim 12 , which comprises spray drying a) an admixture of an aqueous suspension of a phospholipid comprising lung surfactant and an aqueous suspension of 4-(2,6-dichloroanilino)-3-thiophene-acetic acid or b) a solution of a phospholipid comprising lung surfactant and the 4-(2,6-dichloroanilino)-3-thiophene-acetic acid in a suitable solvent, wherein the 4-(2,6-dichlooanilino)-3-thiophene-acetic acid is optionally in the form of a pharmaceuticlaly tolerable salt thereof, to obtain the composition in powder from.
16. A method of elevating the arterial oxygen partial pressure in patients afflicted with IRDS or ARDS, which comprises administering to the patient an effective amount of a composition as claimed in claim 1 .
17. A method to inhibit (or minimize) the formation of hyaline membranes in the lungs of patients afflicted with IRDS or ARDS, which comprises administering to the patient an effective amount of a composition as claimed in claim 1 .